Abstract 1192P
Background
Among neuroendocrine lung cancers, lung carcinoids (LC, further divided into typical [TC] and atypical [AC]) are rare, representing only the 2% of all bronchopulmonary malignancies, and lack prognostic classification and stratification.
Methods
We audited two international cohorts of patients with a confirmed diagnosis of LC for prognostic analysis. We used data from The Christie Hospital (Manchester, UK; N=282) and validated our findings using the cohort of Vall d’Hebron Hospital patients (Barcelona, Spain, N=80). We collected patient data and applied modelling strategies to identify a prognostic model for metastasis-free survival (MFS) and overall survival (OS) from metastatic disease.
Results
Blood lactic dehydrogenase (LDH) and tumour Ki67% were significant at multivariable analysis (stratified for stage) for MFS (C-index=0.69, P=0.0016), while histological subtype (TC vs AC) and other clinical variables were not. Independent prognostic factors for OS from onset of metastases included smoking history, along with known factors (patient age and performance status, proliferation index, PET maximum SUV). The model C-index was 0.84 (P=0.01678), with optimal concordance when applied to the external validation cohort from Vall d’Hebron. Previously undescribed, patients with smoking history lived shorter (median OS 34 months vs not reached, P<0.0001), and our data also suggested that the median OS could be shorter in current smokers (26.2 months) compared to ex-smokers (35.3 months).
Conclusions
We provide a novel prognostic tool to estimate patient risk, clinical trial stratification and assist clinical decisions in the rarest lung tumours. LDH blood levels have not been described as prognostic in this disease, so provide a new reliable biomarker to stratify MFS. We also describe for the first time that smoking history is an independent prognostic factor for overall survival in this cancer. Our results warrant to update the prognostic factors for LC and provide evidence to recommend that patients should stop smoking.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Valpione: Other, Institutional, Research Grant: Amgen. G. Lord: Financial Interests, Personal and Institutional, Advisory Board: Gritstone Bio. W. Mansoor: Financial Interests, Institutional, Advisory Board: Ipsen, Novartis, Pfizer, MSD, BMS, Servier, Amgen; Financial Interests, Institutional, Research Grant: Nordic, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13
1120P - Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Presenter: Robert Stassen
Session: Poster session 13
1121P - Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1122P - Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Presenter: Maria Menezes
Session: Poster session 13
1123P - Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Presenter: Mark Schuiveling
Session: Poster session 13
1124P - IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Presenter: Domenico Mallardo
Session: Poster session 13
1125P - Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Presenter: Benjamin Fairfax
Session: Poster session 13
1126P - REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Presenter: Motoo Nomura
Session: Poster session 13
1127P - Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Presenter: James Pham
Session: Poster session 13
1128P - A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Presenter: Sapna Patel
Session: Poster session 13